Back to News
Market Impact: 0.35
Genmab A/S Announces Positive Topline Results from Phase 3 RAINFOL-02 Trial
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Genmab announced positive topline results from the global Phase 3 RAINFOL-02 trial of investigational ADC rinatabart sesutecan (Rina-S) in patients with an unspecified condition. The available article text provides no efficacy or safety figures, so the magnitude and clinical significance of the results cannot be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
GMAB0.75
More News
- Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- Boeing 777 freighter output halted for two months over supplier row
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say